Donghee Kim1, George Cholankeril1, Andrew A Li2, Won Kim3, Sean P Tighe1, Bilal Hameed4, Paul Y Kwo1, Stephen A Harrison5, Zobair M Younossi6, Aijaz Ahmed1. 1. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. 2. Department of Medicine, Stanford University School of Medicine, Stanford, California, USA. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul, Korea. 4. Division of Gastroenterology and Hepatology, University of California San Francisco - UCSF Health, San Francisco, California, USA. 5. Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom. 6. Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, Virginia, USA.
Abstract
BACKGROUND & AIMS: Current estimates of the population-based disease burden of liver failure or end-stage liver disease (ESLD) are lacking. We investigated recent trends in hospitalizations and in-hospital mortality among patients with ESLD in the United States (US). METHODS: A retrospective analysis was performed utilizing the National Inpatient Sample from 2005 to 2014. We defined ESLD as either decompensated cirrhosis or hepatocellular carcinoma (HCC), criteria obtained from the International Classification of Diseases, Ninth Revision. Nationwide rates of hospitalization and in-hospital mortality were analysed from 2005 to 2014. RESULTS: Hospitalization rates for decompensated cirrhosis during this period increased from 105.3/100 000 persons to 159.9/100 000 persons. In terms of HCC, hospitalization rates increased from 13.6/100 000 to 22.1/100 000. In patients with non-alcoholic fatty liver disease (NAFLD)-related decompensated cirrhosis, the hospitalization rate increased from 13.4/100 000 to 32.1/100 000 with an annual incremental increase of 10.6%, a magnitude twofold higher than other aetiologies. The proportion of NAFLD among hospitalizations with ESLD steadily increased from 12.7% to 20.1% for decompensated cirrhosis while the proportion of chronic hepatitis C (HCV) and alcoholic liver disease (ALD) declined (from 29.3% to 27.6% for HCV; from 39.0% to 37.4% for ALD). Although the overall in-hospital mortality rates for ESLD declined during the study, mortality rates for NAFLD-related decompensated cirrhosis showed no significant change. CONCLUSIONS: Among aetiologies of chronic liver disease, NAFLD demonstrated the fastest growing rate of hospitalizations in non-HCC patients with ESLD in the US. Our study highlights the need for a focus on NAFLD-related hospitalizations and its impact on resource utilization.
BACKGROUND & AIMS: Current estimates of the population-based disease burden of liver failure or end-stage liver disease (ESLD) are lacking. We investigated recent trends in hospitalizations and in-hospital mortality among patients with ESLD in the United States (US). METHODS: A retrospective analysis was performed utilizing the National Inpatient Sample from 2005 to 2014. We defined ESLD as either decompensated cirrhosis or hepatocellular carcinoma (HCC), criteria obtained from the International Classification of Diseases, Ninth Revision. Nationwide rates of hospitalization and in-hospital mortality were analysed from 2005 to 2014. RESULTS: Hospitalization rates for decompensated cirrhosis during this period increased from 105.3/100 000 persons to 159.9/100 000 persons. In terms of HCC, hospitalization rates increased from 13.6/100 000 to 22.1/100 000. In patients with non-alcoholic fatty liver disease (NAFLD)-related decompensated cirrhosis, the hospitalization rate increased from 13.4/100 000 to 32.1/100 000 with an annual incremental increase of 10.6%, a magnitude twofold higher than other aetiologies. The proportion of NAFLD among hospitalizations with ESLD steadily increased from 12.7% to 20.1% for decompensated cirrhosis while the proportion of chronic hepatitis C (HCV) and alcoholic liver disease (ALD) declined (from 29.3% to 27.6% for HCV; from 39.0% to 37.4% for ALD). Although the overall in-hospital mortality rates for ESLD declined during the study, mortality rates for NAFLD-related decompensated cirrhosis showed no significant change. CONCLUSIONS: Among aetiologies of chronic liver disease, NAFLD demonstrated the fastest growing rate of hospitalizations in non-HCC patients with ESLD in the US. Our study highlights the need for a focus on NAFLD-related hospitalizations and its impact on resource utilization.
Authors: Michelle Carbonneau; Ejemai Amaize Eboreime; Ashley Hyde; Denise Campbell-Scherer; Peter Faris; Leah Gramlich; Ross T Tsuyuki; Stephen E Congly; Abdel Aziz Shaheen; Matthew Sadler; Marilyn Zeman; Jude Spiers; Juan G Abraldes; Benjamin Sugars; Winnie Sia; Lee Green; Dalia Abdellatif; Jeffrey P Schaefer; Vijeyakumar Selvarajah; Kaleb Marr; David Ryan; Yolande Westra; Neeja Bakshi; Jayant C Varghese; Puneeta Tandon Journal: BMC Health Serv Res Date: 2020-06-18 Impact factor: 2.655
Authors: Abdel Aziz Shaheen; Kristine Kong; Christopher Ma; Chelsea Doktorchik; Carla S Coffin; Mark G Swain; Kelly W Burak; Stephen E Congly; Samuel S Lee; Matthew Sadler; Meredith Borman; Juan G Abraldes Journal: Clin Gastroenterol Hepatol Date: 2021-10-26 Impact factor: 13.576
Authors: Marilyn D Thomas; Eric Vittinghoff; Stephen Crystal; James Walkup; Mark Olfson; Mandana Khalili; Priya Dahiya; Walker Keenan; Francine Cournos; Christina Mangurian Journal: Schizophr Bull Open Date: 2022-01-12